6 results about "Dalbavancin" patented technology

The present disclosure relates to a stable aqueous composition of dalbavancin, the process for making such compositions and use of such compositions for treatment of a patient in need thereof.

The invention relates to the technical field of medicine preparation, in particular to a synthesis method of dalbavancin demethylated B2 nitrosamine. The synthesis method comprises the following steps: S1, taking a dalbavancin precursor A-40926-B0 as a raw material, and carrying out methylation reaction to obtain an intermediate I; s2, performing esterification protection on the intermediate I to obtain an intermediate II; s3, carrying out condensation reaction on the intermediate II and 3-methylaminopropylamine to obtain an intermediate III, and carrying out alkaline hydrolysis to obtain an intermediate IV; s4, carrying out nitrosation on the intermediate IV through a nitrosation reagent to obtain dalbavancin demethylated B2 nitrosamine; the synthesis method is high in reaction yield, the purity of the demethylated B2 nitrosamine compound of the dalbavancin can be as high as that of the dalbavancin, and a reference substance is provided for quality control of the dalbavancin.

The invention relates to the technical field of medicine preparation, in particular to a method for preparing a nitrosamine compound. The method comprises the following steps: S1, carrying out esterification protection by taking a dalbavancin precursor A-40926-B0 as a raw material to obtain an intermediate I; s2, carrying out condensation reaction on the intermediate I and 3-methylaminopropylamine to obtain an intermediate II, and carrying out alkaline hydrolysis to obtain an intermediate III; s3, protecting secondary amine on a parent nucleus of the intermediate III through a protective reagent to obtain an intermediate IV; s4, carrying out nitrosation on the intermediate IV through a nitrosation reagent to obtain an intermediate V; s5, after the intermediate V is subjected to deprotection, dalbavancin demethylated B0 nitrosamine is obtained; the product prepared by the method is high in purity, a reference substance can be provided for quality control of dalbavancin, and important guiding significance is provided for safe medication.

The invention relates to application of dalbavancin in preparation of a medicine for preventing and / or treating chikungunya virus infection, and belongs to the technical field of biological medicine. According to the application, the anti-chikungunya virus activity of the dalbavancin is researched by selecting the dalbavancin, and an in-vitro cell experiment proves that the duplication and gene expression of the chikungunya virus can be effectively inhibited by exogenously adding the dalbavancin, so that the obvious antiviral activity is shown, and the dalbavancin is proved to have an obvious inhibition effect on the chikungunya virus; and the dalbavancin has anti-chikungunya virus activity at the cellular level, so that the feasibility of the dalbavancin in preparation of drugs for preventing and / or treating chikungunya virus infection is determined, and a new potential drug is provided for prevention and / or treatment of chikungunya virus infection.

The present invention relates to stable aqueous ready-to-dilute compositions of dalbavancin or physiologically acceptable salts thereof, which are suitable for intravenous administration. The aqueous formulation provides improved long-term stability upon storage and does not require reconstitution prior to administration. This application relates to stable aqueous dalbavancin compositions and its use in the treatment of bacterial infections.

A method of using an aqueous solution of propylene glycol to inhibit degradation of dalbavancin hydrochloride, a dalbavancin injection formulation, a preparation method and a method of using the same are provided. In the method of using the aqueous solution of propylene glycol to inhibit degradation of dalbavancin hydrochloride, the volume ratio of propylene glycol to water for injection in the aqueous solution of propylene glycol is 2:8-6:4. In the dalbavancin injection formulation, the concentration of dalbavancin hydrochloride is 20-120 mg / mL, calculated as dalbavancin free base.